FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for …
WEBBLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review ...
WEBJan 21, 2021 · The first drug in its class, belantamab mafodotin-blmf (brand name Blenrep) is a novel therapeutic agent recently approved by the FDA to treat relapsed or treatment-refractory multiple myeloma. Belamaf is an immunoconjugate anti-B-cell maturation antigen with high specificity for multiple myeloma cells [ 7 ] .
GSK announces positive results from DREAMM-8 phase III trial for ...
WEBMar 7, 2024 · DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma. Available at: https://www.gsk.com/en-gb/media/press-releases/dreamm-7-phase-iii-trial-shows-pfs-improvement-and-strong-os-trend-for-blenrep-combo-versus-soc ...
Belantamab mafodotin - Wikipedia
WEBBelantamab mafodotin is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
DREAMM-7 phase III trial shows Blenrep combination nearly tripled ... - GSK
WEBFeb 5, 2024 · The DREAMM-7 phase III clinical trial is a multicentre, open-label, randomised trial evaluating the efficacy and safety of belantamab mafodotin in combination with bortezomib and dexamethasone (BorDex) compared to a combination of daratumumab and BorDex in patients with relapsed/refractory multiple myeloma who previously were treated with at ...
FDA granted accelerated approval to belantamab mafodotin-blmf …
WEBOn August 5, 2020, the Food and Drug Administration granted accelerated approval to belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline) for adult patients with relapsed or refractory multiple...
Phase III Blenrep Trial | Int'l Myeloma Foundation
WEBOn November 27, 2023, GSK announced positive results from the DREAMM-7 phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. The trial demonstrated a significant improvement in progression-free survival (PFS) when belantamab mafodotin was combined with bortezomib and ...
FDA Approval Summary: Belantamab Mafodotin for Patients with …
WEBNov 1, 2022 · On August 5, 2020, the FDA granted accelerated approval to belantamab mafodotin-blmf (BLENREP; GlaxoSmithKline) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome in ….
DREAMM-8 Phase III Trial for Blenrep | Int'l Myeloma Foundation
WEBMar 7, 2024 · GSK press releases reports on positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma.
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
WEBJun 2, 2024 · Triplet or quadruplet therapies incorporating proteasome inhibitors, immunomodulators, and anti-CD38 antibodies have led to prolonged survival among patients with newly diagnosed multiple...
Skip to content